gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-2016Research ArticleНАЦИОНАЛЬНАЯ ШКОЛА ГАСТРОЭНТЕРОЛОГОВ, ГЕПАТОЛОГОВNATIONAL COLLEGE OF GASTROENTEROLOGISTS, HEPATOLOGISTSСовременные подходы к лечению диареи путешественниковModern approach to travellers diarrhea treatmentШептулинА. А.SheptulinA. A.2008261120081866467Copyright © Шептулин А.А., 20082008Шептулин А.А.Sheptulin A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/2016

Цель обзора. Показать этиологические факторы, особенности клинической картины и современные подходы к лечению диареи путешественников.Основные положения обзора. Диарея путешественников чаще всего возникает при поездках в тропические страны. К ее возникновению предрасполагает низкий санитарно­гигиенический уровень в стране пребывания, а возбудителем в большинстве случае служат энтеротоксигенные штаммы E. coli. Основное место в лечении отводится регидратационной терапии, а также назначению антибиотиков. При этом невсасывающиеся антибиотики (рифаксимин) обладают целым рядом преимуществ по сравнению с системно действующими антибиотиками.Заключение. Соблюдение мер профилактики позволяет снизить риск возникновения диареи путешественников, а регидратационная терапия с назначением невсасывающихся антибиотиков помогает быстрее купировать клинические симптомы заболевания.

The aim of review

The aim of review. To define etiological factors, features of clinical pattern and up-to-date approaches to treatment of travellers diarrhea.

Original positions of the review. Travellers diarrhea most often develops at visits to tropical countries. In the majority of cases low sanitary-and-hygienic level in host country contributes to its development, and etiological agent is enterotoxigenic strains E. coli. The basic role in treatment is given to rehydration therapy, and prescription of antibiotics. Thus nonabsorbable antibiotics (rifaximin) have a lot of advantages in comparison to systemically acting antibiotics.

Conclusion

Conclusion. Keeping of prophylactic measures allows to decrease the risk of development of travellers diarrhea, and rehydration therapy with prescription of nonabsorbable antibiotics helps to stop clinical signs of disease faster.

диарея путешественниковфакторы рискарифаксиминtravellers diarrhearisk factorsrifaximinReferencesCastelli F., Saleri N., Tomasoni L.R., Carosi G. Prevention and treatment of traveler’s diarrhea. Focus on antimicrobial agents // Bacterial flora in digestive disease. Focus on Rifaximin / Eds. C. Scarpignato, A. Lanas. – Basel: Karger, 2006. – P. 174–190.Castelli F., Saleri N., Tomasoni L.R., Carosi G. Prevention and treatment of traveler’s diarrhea. Focus on antimicrobial agents // Bacterial flora in digestive disease. Focus on Rifaximin / Eds. C. Scarpignato, A. Lanas. – Basel: Karger, 2006. – P. 174–190.DuPont H.L., Ericsson C.D., Mathewson J.J. et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers’ diarrhea // Digestion. – 1998. – Vol. 59. – P. 708–714.DuPont H.L., Ericsson C.D., Mathewson J.J. et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers’ diarrhea // Digestion. – 1998. – Vol. 59. – P. 708–714.DuPont H.L., Zhi-Dong Jiang, Okhuysen P.C. et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea // Ann. Intern. Med. – 2005. – Vol. 142. – P. 805–812.DuPont H.L., Zhi-Dong Jiang, Okhuysen P.C. et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea // Ann. Intern. Med. – 2005. – Vol. 142. – P. 805–812.Farthing M.J.G. Antisecretory drugs for diarrheal disease // Recent advances in gastrointestinal pharmacology and therapeutics / Eds. C. Scarpignato, F. Di Mario. – Basel: Karger, 2006. – P. 74–94.Farthing M.J.G. Antisecretory drugs for diarrheal disease // Recent advances in gastrointestinal pharmacology and therapeutics / Eds. C. Scarpignato, F. Di Mario. – Basel: Karger, 2006. – P. 74–94.Gascon J. Epidemiology, etiology anf pathophysiology of traveler’s diarrhea // Bacterial flora in digestive disease. Focus on Rifaximin / Eds. C. Scarpignato, A. Lanas. – Basel: Karger, 2006. – P. 162–173.Gascon J. Epidemiology, etiology anf pathophysiology of traveler’s diarrhea // Bacterial flora in digestive disease. Focus on Rifaximin / Eds. C. Scarpignato, A. Lanas. – Basel: Karger, 2006. – P. 162–173.Jiang Z.D., DuPont H.L. Rifaximin: in vitro and in vivo antibacterial activity – a review // Chemotherapy. – 2005. – Vol. 51. (suppl. 1). – P. 67–72.Jiang Z.D., DuPont H.L. Rifaximin: in vitro and in vivo antibacterial activity – a review // Chemotherapy. – 2005. – Vol. 51. (suppl. 1). – P. 67–72.Johnson S., Schriever Ch., Galang M. Interruption of recurrent Clostridium difficile associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Brief report // Clin. Infect. Dis. – 2007. – Vol. 44. – P. 1–3.Johnson S., Schriever Ch., Galang M. Interruption of recurrent Clostridium difficile associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Brief report // Clin. Infect. Dis. – 2007. – Vol. 44. – P. 1–3.Scarpignato C., Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic // Bacterial flora in digestive disease. Focus on Rifaximin / Eds. C. Scarpignato, A. Lanas. – Basel: Karger, 2006. – P. 15–39.Scarpignato C., Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic // Bacterial flora in digestive disease. Focus on Rifaximin / Eds. C. Scarpignato, A. Lanas. – Basel: Karger, 2006. – P. 15–39.Steffen R., Sack D.A., Riopel L. et al. Therapy of travelers’ diarrhea with rifaximin on various continents // Am. J. Gastroenterol. – 2003. – Vol. 98. – P. 1073–1078.Steffen R., Sack D.A., Riopel L. et al. Therapy of travelers’ diarrhea with rifaximin on various continents // Am. J. Gastroenterol. – 2003. – Vol. 98. – P. 1073–1078.Taylor D.N., Bourgeois A.L., Ericsson C.D. et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers’ diarrhea // Am. J. Trop. Med. Hyg. – 2006. – Vol. 74. – P. 1060–1066.Taylor D.N., Bourgeois A.L., Ericsson C.D. et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers’ diarrhea // Am. J. Trop. Med. Hyg. – 2006. – Vol. 74. – P. 1060–1066.Wingate D., Phillips S.E., Lewis S.J. et al. – Guidelines for adults on self-medication for the treatment of acute diarrhea // Aliment. Pharmacol. Ther. – 2001. – Vol. 15. – P. 773–782.Wingate D., Phillips S.E., Lewis S.J. et al. – Guidelines for adults on self-medication for the treatment of acute diarrhea // Aliment. Pharmacol. Ther. – 2001. – Vol. 15. – P. 773–782.

The authors declare that there are no conflicts of interest present.